Skip to main content Back to Top
Advertisement

3/30/2021

Interferon alfa-2b Injection

Products Affected - Description

    • Intron A injection, Merck, 10 million units, vial, 1 count, NDC 00085-4350-01
    • Intron A injection, Merck, 18 million units, vial, 1 count, NDC 00085-4351-01
    • Intron A injection, Merck, 50 million units, vial, 1 count, NDC 00085-4352-01
    • Intron A injection, Merck, 10 million units/mL, 2.5 mL vial, 1 count, NDC 00085-1133-01
    • Intron A injection, Merck, 6 million units/mL, 3 mL vial, 1 count, NDC 00085-1168-01

Reason for the Shortage

    • Merck has made a business decision to discontinue all presentations of Intron A.
    • They are the sole suppliers of interferon alfa-2b.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Merck has discontinued all presentations of Intron A solution for injection. They expect product to be depleted by mid- to late-July 2021.
    • Merck has discontinued all presentations of Intron A powder for injection. They expect product to be depleted by mid- to late-March 2022.

Updated

Created March 30, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.